Articulate Biosciences
Articulate Biosciences, a Boston University spin-off, develops gels to treat arthritis and soft tissue diseases.
Founded
2016Articulate Biosciences, a Boston University spin-off, develops gels to treat arthritis and soft tissue diseases.
Articulate Biosciences, founded in 2016 as a spin-off from Boston University, is a preclinical stage medical device company focused on developing viscoelastic gels for the treatment of arthritis and other soft tissue diseases. Their core mission is to relieve pain and restore mobility for sufferers of osteoarthritis through biocompatible, cushioning, and lubricating biomedical polymers. The company's flagship product candidate aims to provide tissue protection and functional restoration, addressing a significant market need in the medical field.
Notable affiliated individuals include Benjamin Cooper, who plays a key role in the company's leadership. Articulate Biosciences has garnered attention for its innovative approach and potential impact on treating osteoarthritis, a condition affecting millions globally. The company's development of ABX viscoelastics represents a significant advancement in medical technology, promising improved quality of life for patients with degenerative joint diseases.
Companies similar to Articulate Biosciences include Asante Bio, Articulinx, Flex Biomedical and CartilaGen.
Articulate Biosciences was founded in 2016.
Articulate Biosciences' headquarters is located in Lowell, MA, US.
Articulate Biosciences' most recent funding round was for $224.9k (USD) in June 2018.
As of Jun 13, 2018, Articulate Biosciences has disclosed funding of $224.9k (USD). Undisclosed round amounts are excluded.
Articulate Biosciences has 5 employees as of Feb 4, 2024.
CartilaGen
cartilagen.com
